This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurogenetics  • Genetic Counseling/ Testing/ Therapy  • Genetics, Other  • Alert me on articles by topic

Back From the Future

Arch Neurol. 2001;58:1766-1767.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

YOUR PATIENT is a 61-year-old man with the slow onset of some recent stiffness predominantly in the left arm and hand, some clumsiness when walking, and a slight pill-rolling tremor of the left hand. Further physical examination is consistent with the diagnosis of early Parkinson disease (PD). Magnetic resonance imaging and ligand-specific positron emission tomography studies confirm the diagnosis. Examination of the polymorphic variations of the parkin gene and the other major PD susceptibility genes determines PD type 7, which has a mean age of onset of 61 to 64 years.

The patient's microdisk containing his standard genome variations profile (SGVP) as well as other personal medical and financial profiles is inserted into the electronic Physician's Desk Reference Reader linked to the updated database for pharmacogenetic data, covering adverse events and efficacy data for all medicines registered during the past 20 years. The new diagnosis of PD7 is entered, and . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Biomarkers of Cancer Risk and Therapeutic Benefit: New Technologies, New Opportunities, and Some Challenges
Macgregor
Toxicol Pathol 2004;32:99-105.
ABSTRACT  

The Future of Regulatory Toxicology: Impact of the Biotechnology Revolution
MacGregor
Toxicol Sci 2003;75:236-248.
ABSTRACT | FULL TEXT